Palbociclib
Back to searchMolecule Structure
Scientific Name
Palbociclib
Description of the Drug
Palbociclib is an endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09073
http://www.drugbank.ca/drugs/DB09073
Brand Name(s)
Ibrance
Company Owner(s)
Pfizer Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
CDK6/cyclin D1 | PROTEIN COMPLEX | INHIBITOR | CHEMBL2111455 |
Cyclin-dependent kinase 4/cyclin D1 | PROTEIN COMPLEX | INHIBITOR | CHEMBL1907601 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL462630 | |
PharmGKB | PA166153469 | |
Human Metabolome Database | HMDB0256084 | |
DrugBank | DB09073 | |
PubChem: Thomson Pharma | 14808444 | |
PubChem | 5330286 | |
LINCS | LSM-1071 | |
Nikkaji | J3.007.984A | |
PDBe | LQQ | |
BindingDB | 6309 | |
DrugCentral | 4941 | |
Brenda | 213642 | 213667 |
ChemicalBook | CB62464897 | |
Guide to Pharmacology | 7380 | |
rxnorm | PALBOCICLIB | IBRANCE |
PubChem: Drugs of the Future | 12015755 | |
ChEBI | 85993 | |
ZINC | ZINC000003938686 |